SCHEMBL4664973

SCHEMBL4664973

CC(C)CC1OC(=O)C(C(=O)CCCc2ccccc2)=C1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 6/20 0.47
CDC25B P30305 6/20 0.47
ACP1 P24666 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
HPSE Q9Y251 2/20 0.47
DUSP3 P51452 2/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
PTPN2 P17706 1/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 1/20 0.45
PKM P14618 1/20 0.45
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CDC25A P30304 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4662972 0.93 PTPN1 (0.43) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4666595 0.90 PTPN1 (0.44) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4664852 0.85 TDP1 (0.49) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4664800 0.82 ALDH1A1 (0.44) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4664722 0.82 ALDH1A1 (0.46) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4663030 0.82 PTPN1 (0.41) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4663353 0.80 DUSP3 (0.45) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4664815 0.79 CDC25B (0.48) PTPN1CDC25BACP1DUSP3CASP3
SCHEMBL4666574 0.78 PTPN1 (0.38) PTPN1CDC25BACP1TDP1HPSE
SCHEMBL4665112 0.78 HPGD (0.39) PTPN1CDC25BACP1TDP1HPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US claimed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US claimed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US disclosed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 PTPN1 2489/4885CDC25B 3121/4885ACP1 2849/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 PTPN1 2489/4885CDC25B 3121/4885ACP1 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.